Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
Status:
Completed
Trial end date:
2016-06-15
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability
of treatment with sofosbuvir/velpatasvir (SOF/VEL) in participants with chronic genotype 1,
2, 4, 6 or indeterminate HCV infection who received placebo in the Gilead-sponsored study
GS-US-342-1138.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Sofosbuvir Sofosbuvir-velpatasvir drug combination Velpatasvir